Collegium Pharmaceutical Inc. (COLL) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Collegium Pharmaceutical Inc. (COLL:NASDAQ), powered by AI.

Current Price
$34.64
P/E Ratio
17.5
Market Cap
1.1B
Sector
Healthcare
What is the Collegium Pharmaceutical Inc. stock price forecast?

Collegium Pharmaceutical Inc. is currently trading at $34.64. View real-time AI analysis on Alpha Lenz.

What is Collegium Pharmaceutical Inc. insider trading activity?

View the latest insider trading data for Collegium Pharmaceutical Inc. on Alpha Lenz.

What is Collegium Pharmaceutical Inc.'s P/E ratio?

Collegium Pharmaceutical Inc.'s P/E ratio is 17.5.

Collegium Pharmaceutical Inc.

NASDAQ · COLL
$34.64+0.30(+0.87%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Collegium Pharmaceutical Inc.'s future dividend policy...
Alpha Chat Insight

Collegium Pharmaceutical Inc. trades at a P/E of 17.5 (fair value) with strong ROE of 23.7%. 3Y revenue CAGR of 18.9% highlights clear growth momentum.

Ask for details

Company Overview

Collegium Pharmaceutical Inc. is a biotechnology company specializing in the development and commercialization of innovative medications aimed at addressing under-treated medical conditions in pain management. The company places significant emphasis on creating abuse-deterrent formulations of opioid and non-opioid medications, which are crucial in the context of the ongoing opioid crisis. Collegium Pharmaceutical’s products such as Xtampza ER, an extended-release oral formulation used for managing chronic pain, highlight its commitment to safer medication options. Operating primarily within the healthcare sector, the company collaborates with medical professionals and institutions to promote best practices in pain medication prescription and use. Headquartered in Stoughton, Massachusetts, Collegium Pharmaceutical plays a vital role in the pharmaceutical industry by advancing treatment options that prioritize patient safety and therapeutic efficiency. Through its focus on responsible medication use and innovation, the company seeks to contribute to public health solutions that combat the challenges associated with pain management.

CEOMr. Vikram Karnani
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees357

Company Statistics

FY 2025

Profile

$1.10BMarket Cap
$780.57MRevenue
0.00Shares Out
357Employees

Margins

59.35%Gross
53.27%EBITDA
22.86%Operating
11.87%Pre-Tax
8.05%Net

Valuation

17.47P/E
3.64P/B
1.41EV/Sales
4.04EV/EBITDA
3.35P/FCF

Growth (CAGR)

18.94%Rev 3Yr
20.28%Rev 5Yr
74.96%Op Inc 3Yr
25.98%Op Inc 5Yr
N/ANet Inc 3Yr
18.64%Net Inc 5Yr

Returns

3.79%ROA
23.70%ROE
10.54%ROIC

Financial Health

$231.25MCash & Cash Equivalents
$1.12BNet Debt
449.21%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Collegium Pharmaceutical Inc. (ticker: COLL) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 357 employees. Market cap is $1.1B.

The current price is $34.64 with a P/E ratio of 17.47x and P/B of 3.64x.

ROE is 23.70% and operating margin is 22.86%. Annual revenue is $781M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Collegium Pharmaceutical Inc. (COLL) Stock Forecast 2026 $34.64 — Price, Financials & Analyst Targets | Alpha Lenz